Nuformix (LON:NFX) Announces Quarterly Earnings Results

Nuformix (LON:NFX) announced its earnings results on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Nuformix Stock Performance

Shares of Nuformix stock opened at GBX 0.08 ($0.00) on Friday. The company has a current ratio of 1.12, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17. The business has a 50-day moving average price of GBX 0.06 and a two-hundred day moving average price of GBX 0.10. Nuformix has a 1-year low of GBX 0.04 ($0.00) and a 1-year high of GBX 0.34 ($0.00). The company has a market cap of £647,254.90, a P/E ratio of -1.63 and a beta of 1.22.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.